Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:

Biovail Cardizem XL “approvable”

  • News

Executive Summary

Biovail receives "approvable" letter for Cardizem XL, company announces June 17. Approval of the diltiazem extended-release formulation is "subject to the completion of labeling matters and the submission and review of requested information," Biovail says. Biovail is adding 500 reps to its 300-rep sales force in preparation for the launch of Cardizem XL (1"The Pink Sheet" May 20, p. 21)...

You may also be interested in...



Biovail Vasotec/Cardizem Fixed-Dose Combination Data Expected By July

Biovail expects results from a Phase III trial of several fixed-dose combinations of Vasotec and Cardizem XL in the first half of the year

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Table

View full table

Tags:
UsernamePublicRestriction

Register

PS040035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By